On April 28, 2025, Spero Therapeutics announced the appointment of Esther Rajavelu as President and CEO effective May 2, 2025, succeeding Satyavrat Shukla, who is separating from the company with significant financial benefits. Rajavelu's base salary will be $620,000, with a target performance bonus of 50% and 185,000 restricted stock units granted under the company's equity plan.